Insight Advisors LLC PA Grows Position in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Insight Advisors LLC PA boosted its stake in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 38.2% during the first quarter, HoldingsChannel.com reports. The firm owned 40,356 shares of the company’s stock after acquiring an additional 11,164 shares during the period. Insight Advisors LLC PA’s holdings in Global X Genomics & Biotechnology ETF were worth $321,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. SBI Securities Co. Ltd. purchased a new position in shares of Global X Genomics & Biotechnology ETF in the 4th quarter worth about $50,000. Sanctuary Advisors LLC acquired a new stake in Global X Genomics & Biotechnology ETF during the 4th quarter worth approximately $104,000. Sei Investments Co. acquired a new stake in Global X Genomics & Biotechnology ETF during the 4th quarter worth approximately $114,000. Smartleaf Asset Management LLC raised its holdings in Global X Genomics & Biotechnology ETF by 11.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 12,604 shares of the company’s stock valued at $122,000 after buying an additional 1,265 shares during the period. Finally, Atria Investments Inc raised its holdings in Global X Genomics & Biotechnology ETF by 27.8% in the fourth quarter. Atria Investments Inc now owns 13,813 shares of the company’s stock valued at $134,000 after buying an additional 3,006 shares during the period. Hedge funds and other institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Stock Up 3.1%

Shares of GNOM stock opened at $8.36 on Friday. Global X Genomics & Biotechnology ETF has a fifty-two week low of $6.80 and a fifty-two week high of $11.88. The firm’s 50 day moving average price is $7.76 and its two-hundred day moving average price is $9.05. The stock has a market cap of $50.66 million, a price-to-earnings ratio of -3.57 and a beta of 1.03.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.